失代偿性肝硬化-话题@MedSci

#失代偿性肝硬化#

10篇内容 | 1569人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2215703, encodeId=6b0f2215e0323, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a> <a href='/topic/show?id=e550442591f' target=_blank style='color:#2F92EE;'>#失代偿性肝硬化#</a> <a href='/topic/show?id=38d311683307' target=_blank style='color:#2F92EE;'>#恩替卡韦(ETV)#</a>, objectTitle=JHEP Rep：中国学者研究恩替卡韦治疗的乙型肝炎和失代偿性肝硬化患者再代偿的持久性和治疗预测因素, objectType=article, longId=835227, objectId=31db83522ed9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867593143_4754896.jpeg, objectUrl=/article/show_article.do?id=31db83522ed9, replyNumber=0, likeNumber=77, createdTime=2024-07-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=31db83522ed9, moduleTitle=JHEP Rep：中国学者研究恩替卡韦治疗的乙型肝炎和失代偿性肝硬化患者再代偿的持久性和治疗预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31db83522ed9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1502155, encodeId=62601502155cb, content=<a href='/topic/show?id=e550442591f' target=_blank style='color:#2F92EE;'>#失代偿性肝硬化#</a>, objectTitle=J Hepatology: β受体阻滞剂的短期血流动力学影响会对失代偿性肝硬化患者的生存产生负面作用, objectType=article, longId=201792, objectId=2c6d201e9206, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c6d201e9206, replyNumber=0, likeNumber=78, createdTime=2020-10-08, rootId=0, userName=lizhou0207, userId=ecdc9510146, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c6d201e9206, moduleTitle=J Hepatology: β受体阻滞剂的短期血流动力学影响会对失代偿性肝硬化患者的生存产生负面作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c6d201e9206)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1502154, encodeId=9306150215465, content=<a href='/topic/show?id=e550442591f' target=_blank style='color:#2F92EE;'>#失代偿性肝硬化#</a>, objectTitle=Diagn Pathol：Treg/Th17比值可作为预测失代偿性肝硬化的潜在标志物, objectType=article, longId=201611, objectId=f47a201611b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f47a201611b5, replyNumber=0, likeNumber=0, createdTime=2020-10-05, rootId=0, userName=lizhou0207, userId=ecdc9510146, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f47a201611b5, moduleTitle=Diagn Pathol：Treg/Th17比值可作为预测失代偿性肝硬化的潜在标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f47a201611b5)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1502153, encodeId=61b71502153f4, content=<a href='/topic/show?id=e550442591f' target=_blank style='color:#2F92EE;'>#失代偿性肝硬化#</a>, objectTitle=J Gastroenterology：治疗代偿性腹水可减轻肌肉减少症并改善失代偿性肝硬化患者的生存率, objectType=article, longId=187607, objectId=e94e18e6078b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e94e18e6078b, replyNumber=0, likeNumber=107, createdTime=2020-02-08, rootId=0, userName=lizhou0207, userId=ecdc9510146, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e94e18e6078b, moduleTitle=J Gastroenterology：治疗代偿性腹水可减轻肌肉减少症并改善失代偿性肝硬化患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e94e18e6078b)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1502152, encodeId=6a06150215244, content=<a href='/topic/show?id=e550442591f' target=_blank style='color:#2F92EE;'>#失代偿性肝硬化#</a>, objectTitle=J Hepatol：3级肥胖是失代偿性肝硬化患者发生慢加急性肝衰竭的危险因素, objectType=article, longId=147942, objectId=c24b14e94268, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c24b14e94268, replyNumber=0, likeNumber=87, createdTime=2018-09-02, rootId=0, userName=lizhou0207, userId=ecdc9510146, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c24b14e94268, moduleTitle=J Hepatol：3级肥胖是失代偿性肝硬化患者发生慢加急性肝衰竭的危险因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c24b14e94268)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1502151, encodeId=a8a31502151f4, content=<a href='/topic/show?id=e550442591f' target=_blank style='color:#2F92EE;'>#失代偿性肝硬化#</a>, objectTitle=Hepatology：慢加急性肝功能衰竭(ACLF)和失代偿性肝硬化(INR)患者凝血功能衰竭, objectType=article, longId=140002, objectId=ed09140002c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed09140002c7, replyNumber=0, likeNumber=79, createdTime=2018-06-06, rootId=0, userName=lizhou0207, userId=ecdc9510146, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed09140002c7, moduleTitle=Hepatology：慢加急性肝功能衰竭(ACLF)和失代偿性肝硬化(INR)患者凝血功能衰竭, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed09140002c7)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1502150, encodeId=d0de15021504c, content=<a href='/topic/show?id=e550442591f' target=_blank style='color:#2F92EE;'>#失代偿性肝硬化#</a>, objectTitle=Lancet：人白蛋白治疗可提高失代偿性肝硬化患者的生存率, objectType=article, longId=139713, objectId=53d8139e13a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53d8139e13a9, replyNumber=0, likeNumber=75, createdTime=2018-06-03, rootId=0, userName=lizhou0207, userId=ecdc9510146, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53d8139e13a9, moduleTitle=Lancet：人白蛋白治疗可提高失代偿性肝硬化患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53d8139e13a9)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1502149, encodeId=d6c1150214984, content=<a href='/topic/show?id=e550442591f' target=_blank style='color:#2F92EE;'>#失代偿性肝硬化#</a>, objectTitle=EASL临床实践指南：失代偿性肝硬化患者的管理, objectType=article, longId=135570, objectId=c1481355e018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1481355e018, replyNumber=0, likeNumber=62, createdTime=2018-04-18, rootId=0, userName=lizhou0207, userId=ecdc9510146, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1481355e018, moduleTitle=EASL临床实践指南：失代偿性肝硬化患者的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1481355e018)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1502148, encodeId=4f511502148dd, content=<a href='/topic/show?id=e550442591f' target=_blank style='color:#2F92EE;'>#失代偿性肝硬化#</a>, objectTitle=Liver Int：急性肾损伤而败血症是侵入性操作后失代偿性肝硬化患者出血的独立预测因子, objectType=article, longId=129514, objectId=bc5f12951479, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc5f12951479, replyNumber=0, likeNumber=62, createdTime=2018-02-11, rootId=0, userName=lizhou0207, userId=ecdc9510146, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc5f12951479, moduleTitle=Liver Int：急性肾损伤而败血症是侵入性操作后失代偿性肝硬化患者出血的独立预测因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc5f12951479)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1502147, encodeId=7a4a150214e25, content=<a href='/topic/show?id=e550442591f' target=_blank style='color:#2F92EE;'>#失代偿性肝硬化#</a>, objectTitle=J Gastroenterol Hepatol：移植hUCMSCs治疗方法对失代偿性肝硬化患者可能是一个合适的选择, objectType=article, longId=128011, objectId=986b1280116e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=986b1280116e, replyNumber=0, likeNumber=81, createdTime=2018-01-29, rootId=0, userName=lizhou0207, userId=ecdc9510146, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=986b1280116e, moduleTitle=J Gastroenterol Hepatol：移植hUCMSCs治疗方法对失代偿性肝硬化患者可能是一个合适的选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=986b1280116e)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1502146, encodeId=c767150214674, content=<a href='/topic/show?id=e550442591f' target=_blank style='color:#2F92EE;'>#失代偿性肝硬化#</a>, objectTitle=J Hepatol：生存率不降反升卡维地洛对失代偿性肝硬化和腹水患者无害, objectType=article, longId=106945, objectId=27ad10694558, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27ad10694558, replyNumber=0, likeNumber=73, createdTime=2017-07-29, rootId=0, userName=lizhou0207, userId=ecdc9510146, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27ad10694558, moduleTitle=J Hepatol：生存率不降反升卡维地洛对失代偿性肝硬化和腹水患者无害, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27ad10694558)], followStatus=false, userIsMember=true, type=1, lengthMark=0)] 梅斯话题小助手

失代偿性肝硬化

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#慢性乙型肝炎# #失代偿性肝硬化# #恩替卡韦(ETV)#

JHEP Rep：中国学者研究恩替卡韦治疗的乙型肝炎和失代偿性肝硬化患者再代偿的持久性和治疗预测因素

2024-07-19发表于上海

(审核中...)

前往app查看评论内容

#失代偿性肝硬化#

J Hepatology: β受体阻滞剂的短期血流动力学影响会对失代偿性肝硬化患者的生存产生负面作用

2020-10-08

(审核中...)

前往app查看评论内容

#失代偿性肝硬化#

Diagn Pathol：Treg/Th17比值可作为预测失代偿性肝硬化的潜在标志物

2020-10-05

(审核中...)

前往app查看评论内容

#失代偿性肝硬化#

J Gastroenterology：治疗代偿性腹水可减轻肌肉减少症并改善失代偿性肝硬化患者的生存率

2020-02-08

(审核中...)

前往app查看评论内容

#失代偿性肝硬化#

J Hepatol：3级肥胖是失代偿性肝硬化患者发生慢加急性肝衰竭的危险因素

2018-09-02

(审核中...)

前往app查看评论内容

#失代偿性肝硬化#

Hepatology：慢加急性肝功能衰竭(ACLF)和失代偿性肝硬化(INR)患者凝血功能衰竭

2018-06-06

(审核中...)

前往app查看评论内容

#失代偿性肝硬化#

Lancet：人白蛋白治疗可提高失代偿性肝硬化患者的生存率

2018-06-03

(审核中...)

前往app查看评论内容

#失代偿性肝硬化#

EASL临床实践指南：失代偿性肝硬化患者的管理

2018-04-18

(审核中...)

前往app查看评论内容

#失代偿性肝硬化#

Liver Int：急性肾损伤而败血症是侵入性操作后失代偿性肝硬化患者出血的独立预测因子

2018-02-11

(审核中...)

前往app查看评论内容

#失代偿性肝硬化#

J Gastroenterol Hepatol：移植hUCMSCs治疗方法对失代偿性肝硬化患者可能是一个合适的选择

2018-01-29

(审核中...)

前往app查看评论内容

#失代偿性肝硬化#

J Hepatol：生存率不降反升卡维地洛对失代偿性肝硬化和腹水患者无害

2017-07-29

科室
- - 订阅+
  - 更多科室
工具
服务